BioElectronics Corporation Accelerates Introduction Of Its Market Disruptive Products And Updates Business Strategy

FREDERICK, Md, Aug. 23 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that the future for its ActiPatch, a drug free, anti-inflammatory patch and the Company's underlying mission of inexpensively helping people reduce pain and inflammation while accelerating healing looks very positive. "Through sales and clinical trials, physicians and patients are recognizing the profound anti-inflammatory therapeutic benefit of ActiPatch," said CEO Andy Whelan.

ActiPatch is currently US FDA cleared for the treatment of edema following blepharoplasty and is also approved in Canada and Europe for the relief of pain in muscosketal conditions. Application has been submitted to the FDA for a new product surgical market clearance. The new clinical trials for heel pain and ankle sprains will be used for US sports medicine and orthopedic over the counter product introductions. "We are optimistic that these new FDA market clearances will facilitate a full 2007 US introduction of our repetitive stress products for heel pain, tennis elbow and carpal tunnel syndrome, as well as wraps for back pain, injured knees, wrist and ankles. "This quarter's retail product introduction in Canada will provide insight into direct-to-consumer sales," said Mr. Whelan.

The Company's sales and marketing to physicians is being rapidly expanded by the addition of new US and Canadian distributors consisting of more than 70 independent sales agents. The Company also relocated its Sales and Customer Service division to new offices.

The Company noted that the recent filing of an SEC SB-2 Registration Statement will allow the Company to obtain listing on the OTC: BB has caused some confusion and concern. While the Registration lists 25 million shares being registered, nearly half of the shares are for the potential conversion of the Note Payable and exercise of outstanding warrants at prices up to $.50 per share.

ActiPatch(TM) is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit and

Safe Harbor Statement: This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of the company in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.

Source: BioElectronics Corporation

Back to news